Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / BVS - Bioventus reaffirms FY22 sales outlook cancels $415M notes offering

BVS - Bioventus reaffirms FY22 sales outlook cancels $415M notes offering

Bioventus Inc.
Bioventus (NASDAQ:BVS) reaffirmed its full-year 2022 net sales guidance and withdrew a $415M senior notes offering. The company said that based on current trends in its business, it was reaffirming its full-year 2022 net sales guidance to be in the range of $545M to $565M, including for units Bioness and Misonix. Consensus Revenue Estimate for 2022 is $553.66M. Bioventus (BVS) expects full-year adjusted EBITDA guidance range of $94M to $107M. In addition, Bioventus (BVS) said that its subsidiary has withdrawn the senior notes offering which was announced on April 26, as the company believes that current market conditions are not conducive for an offering on terms that would be in the best interests of its stakeholders. The company noted that it is exploring alternative financing options to finance the upfront consideration of its previously announced call option to acquire CartiHeal.

For further details see:

Bioventus reaffirms FY22 sales outlook, cancels $415M notes offering
Stock Information
Company Name: Bioventus Inc.
Stock Symbol: BVS
Market: NASDAQ
Website: bioventus.com
Menu
BVS BVS Quote BVS Short BVS News BVS Articles BVS Message Board
Get BVS Alerts

News, Short Squeeze, Breakout and More Instantly...